News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Drug Development
Dendreon Corporation Soars on Plans to Present Prostate Study
April 3, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Bloomberg -- Dendreon Corp. rose the most in two years in Nasdaq trading after the company reserved conference space to present data on its prostate cancer drug later this month.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase III
MORE ON THIS TOPIC
IN PARTNERSHIP WITH ECLIPSEBIO
Why Countries Are Racing To Build mRNA Factories While America Hesitates on Next-Gen Vaccines
July 22, 2025
·
1 min read
·
Lori Ellis
Duchenne muscular dystrophy
Sarepta Concedes to FDA Request, Suspends US Shipments of Elevidys
July 22, 2025
·
2 min read
·
Tristan Manalac
Immunology and inflammation
Roche Flunks Phase III Trial in COPD, Falling Further Behind Dupixent
July 21, 2025
·
2 min read
·
Tristan Manalac
Clinical research
BMS’ Anemia Drug Reblozyl Flunks Phase III Myelofibrosis Trial
July 18, 2025
·
2 min read
·
Tristan Manalac
